Nordic Capital takes majority stake in Evosep to scale proteomics

Nordic Capital has agreed to acquire a controlling interest in Evosep, the Danish specialist in rapid, high‑throughput LC‑MS proteomics instrumentation and consumables. The private equity investor will work alongside Evosep’s founders and executive team to scale the business internationally, while existing minority backers EIFO and Novo Holdings will divest their holdings and the founders remain invested.

Founded in 2016, Evosep has built a reputation for simplifying sample preparation and chromatography for mass‑spectrometry workflows, prioritising throughput and reproducibility for translational research and biopharma pipelines. The company’s platform addresses a growing demand for robust protein analytics used in biomarker discovery, therapeutic development and the emerging field of proteomics‑driven diagnostics.

The deal will be executed from Nordic Capital’s healthcare growth vehicle, the Evolution platform, which holds approximately EUR 3.2 billion of committed capital and targets mid‑market companies across northern Europe. Evosep marks the platform’s thirteenth announced investment since its 2021 launch. Financial terms have not been disclosed and the transaction is expected to close in Q4 2025.

Evosep’s chief executive, Morten Bern, said the partnership is intended to accelerate product development and broaden commercial reach. Nordic Capital has a lengthy track record in healthcare tools and diagnostics, a background the firm says will be leveraged to professionalise go‑to‑market execution and support deeper engagement with biopharma clients and clinical laboratories.

The global proteomics and mass‑spectrometry tools market is expanding rapidly as pharmaceutical companies and academic centres push for higher sample throughput and better quantitative consistency. Analysts estimate double‑digit compound annual growth in demand for LC‑MS workflows over the next five years, driven by greater uptake in translational studies and potential diagnostic applications where standardisation is critical.

Jonas Agnblad, Partner and Co‑Head of Nordic Capital Evolution advisory, highlighted Evosep’s strong academic and industry endorsements and signalled plans to invest in commercial infrastructure and product pipeline expansion. With founders and management retaining positions and partial ownership, the transaction aims to combine continuity in scientific leadership with fresh growth capital and execution capacity.